The Edinburgh Science Triangle
Active collaborations across various industries are integral in continuing to develop innovative technologies and major breakthroughs
in scientific research. This is extremely evident in the life sciences where, for instance, engineers are working with biomedical
researchers to advance therapies for several diseases, and in nanotechnology, which is becoming more instrumental in developing
targeted drug delivery. Science parks are emerging around the world, and this is a great opportunity for companies with different
specializations to partner with one another to achieve the same goal: to advance scientific discovery. Scotland has taken
this notion further and formed the Edinburgh Science Triangle (EST,
http://www.edinburgsciencetriangle.com/), which encompasses seven of Scotland's science parks: Center for Biomedical Research (
http://www.scottish-enterprise.com/biomedicalcentre), BioCampus, Alba Campus, Roslin Biocenter, Edinburgh Technopole, Heriot-Watt Research Park, and Pentlands Science Park.
The EST is now one of world's 20 largest science parks, with over 30 years of experience since Europe's first science park
opened at Heriot-Watt University in 1971. The expertise offered by the EST ranges from bioinformatics and stem cell research
to energy and optoelectronics.
Furthermore, the close proximity between academia and industry, with four major universities in the area, broadens the research
capabilities that are available to each of the science parks.
The newest addition to the EST, the Centre for Biomedical Research (CBR), is a $1-billion project that will incorporate commercial,
academic, and clinical ventures with research collaborations. The CBR proposition is based on the co-location of the University
of Edinburgh's internationally acclaimed medical school, the new state-of-the-art teaching hospital, the Royal Infirmary of
Edinburgh, and the Queen's Medical Research Institute. Ian Wilmut, creator of Dolly the sheep, is head of the Center for Regenerative
Medicine, which is also based at the CBR, and will be overseeing stem cell research aimed at developing therapeutic treatments
for diseases such as cancer, diabetes, and Parkinson's disease. As a whole, the CBR will be commercializing its research and
will put Edinburgh on the map as one of the world's top biomedical research and development centers.
In addition, another center of excellence for stem cell research, bioinformatics, and genomics in the EST is the Roslin BioCenter
http://www.roslinbiocentre.co.uk/). Roslin BioCenter is a science park developed around Roslin Institute, most notable for being the birthplace of Dolly the
sheep. The Roslin Institute (
http://www.roslin.ac.uk/) continues to be one of the world's leading centers for animal biotechnology and farm animal genetics. Most recently, Roslin
Institute established a non-profit company, Roslin Cells Ltd (
http://www.roslincells.com/), in which Paul De Sousa, MD, will lead a team of researchers in commercializing human stem cell lines worldwide without
intellectual property rights. Moreover, some companies such as Geron Bio-Med (
http://www.geron.com/), Nexus Oncology (
http://www.nexusoncology.com/), and also Genecom (
http://www.genecombio.com/) allow Roslin BioCenter to offer others the opportunity to become part of a top scientific community, especially in the areas
of genomics and bioinformatics. In fact, Edinburgh is already home to the Edinburgh Center for Bioinformatics (
http://www.bioinformatics.ed.ac.uk/) and the UK National e-Science Center (